DOCSLIB.ORG

Download 14 Drug Testing Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download 14 Drug Testing Guide BEFORE YOU TEST UNDERSTANDING YOUR TEST – INTERPRETATION OF RESULTS • Read these instructions completely. The complete First Check® Home Drug Test kit tests for 14 drugs, 7 illicit and 7 prescription. ® • Have a watch, clock or timer available. The Test Lid has 7 Test Strips in total. Each has 2 Drug Names per Test Strip. They will be identified as Drug 1 and Drug 2. • Do Not Open the Test Lid until you are ready to perform the test. 14 Drugs Tested: ® • Do not use test if it is beyond the expiration date printed on 7 Illicit: 7 Prescription: Drug1 the pouch. Do not use test if the pouch is torn or punctured. THC 1: THC 1: OPI 1: OPI 1: AMP 1: AMP 1: BAR 1: BAR 1: BUPG 1: BUPG 1: MDMA 1: MDMA 1: PCP 1: PCP 1: Marijuana (THC) Tricyclic Antidepressants (TCA) Drug2 HOME DRUG TEST • The test is for one time use only. It is not reusable. COC 2: COC 2: MET 2: MET 2: BZO 2: BZO 2: MTD 2: MTD 2: TCA 2: TCA 2: OXY 2: OXY 2: PPX 2: PPX 2: Cocaine (COC) Barbituates (BAR) Ctrl Control D1 Drug 1 Opiates (heroin) (OPI) Benzodiazepines (BZO) • Certain foods or medications may cause the test to give false D2 Drug 2 results. RESULTS KEY Methamphetamine (MET) Methadone (MTD) Negative Preliminary Positive Invalid Control Control Control Ecstasy (MDMA) Oxycodone (OXY) • Contaminated or tainted urine sample may give false results. Drug1 Drug1 Drug1 Product Instructions Drug2 Drug2 Drug2 Amphetamines (AMP) Buprenorphine (BUPG) • Do not use this test if you are color-blind. firstcheckfamily.com • First Check® Home Drug Tests offer a variety of solutions for Phencyclidine (PCP) Propoxyphene (PPX) TESTING MATERIALS fast, accurate and reliable drug testing in the privacy of your The following materials are for testing an individual urine sample own home. This test can detect the possible use of up to 7 illicit Each strip contains two drug tests. The Ctrl region shows validity in your home: and 7 prescription drugs. of a test result. The D1 region shows the result for Drug 1. • Test Lid (in foil pouch) Drug 1 row tests for: Drug 1 • This test provides only preliminary results and is the first step in The D2 region shows the result for Drug 2. THC, OPI, AMP, BAR, a two-step process for identifying drugs in urine. • Collection Cup BUPG, MDMA, PCP 1: THC 1: THC 1: OPI 1: OPI 1: AMP 1: AMP 1: BAR 1: BAR 1: BUPG 1: BUPG 1: MDMA 1: MDMA 1: 1: PCP 1: PCP 1: • Product Instructions For Ctrl (Control) region: Drug 2 row tests for: Drug 2 • The second step is confirming the results with Gas The appearance of a line indicates a valid result. No line means an COC, MET, BZO, MTD, TCA, OXY, PPX 2: TCA 2: TCA 2: Chromatography-Mass Spectrometry (GC-MS) or Liquid Set aside these items, you will only need these if you ship the Invalid result. If a test strip does not have a line in the Ctrl region, COC 2: COC 2: MET 2: MET 2: BZO 2: BZO 2: MTD 2: MTD 2: OXY 2: OXY 2: PPX 2: PPX 2: Chromatography-Tandem Mass Spectrometry (LC-MS/MS) at sample for confidential confirmatory lab testing: Ctrl region: test results are Invalid for both D1 and D2 on that strip. shows validity for each strip Ctrl our certified laboratory. • Pre-addressed Mailing box D1 region: shows results for D1 Drug 1 on each strip • To confirm preliminary positive results obtained by the First • Plastic Transportation Bag For D1 (Drug 1) and D2 (Drug 2) regions: D2 ® The appearance of a line indicates a Negative result. D2 region: shows results for Check Home Drug Test Kit, use the included mailer and follow • Identification Label Drug 2 on each strip steps outlined in these instructions. There is no cost to utilize our Note: Any test line, even a very faint test line, is considered a lab to confirm preliminary positive results of the drugs included STORAGE negative result. in the lid. Store the First Check Home Drug Test at room temperature 59˚F to 86˚F (15˚C to 30˚C). No line indicates a Preliminary Positive result. Note: Any urine with preliminary positive results should be sent to a laboratory for confirmation. WHEN YOU ARE READY TO TEST Drug 1 Drug 1 FOLLOW THESE STEPS: Example #1: There is a line Drug 1 Example #2: There is no line appearing in both D1 and D2 appearing in the D1 region 1: THC 1: THC 1: OPI 1: OPI 1: AMP 1: AMP 1: BAR 1: BAR 1: BUPG 1: BUPG 1: MDMA 1: MDMA 1: 1: PCP 1: PCP 1: 1: THC 1: THC 1: OPI 1: OPI 1: AMP 1: AMP 1: BAR 1: BAR 1: BUPG 1: BUPG 1: MDMA 1: MDMA 1: 1: PCP 1: PCP 1: 1: THC 1: THC 1: OPI 1: OPI 1: AMP 1: AMP 1: BAR 1: BAR 1: BUPG 1: BUPG 1: MDMA 1: MDMA 1: 1: PCP 1: PCP 1: Drug 2 Drug 2 regions on all test strips. Drug 2 on the first test strip. 2: TCA 2: TCA 2: 2: COC 2: COC 2: MET 2: MET 2: BZO 2: BZO 2: MTD 2: MTD 2: OXY 2: OXY 2: PPX 2: PPX 2: 2: TCA 2: TCA 2: 2: COC 2: COC 2: MET 2: MET 2: BZO 2: BZO 2: MTD 2: MTD 2: OXY 2: OXY 2: PPX 2: PPX 2: 2: TCA 2: TCA 2: 2: COC 2: COC 2: MET 2: MET 2: BZO 2: BZO 2: MTD 2: MTD 2: OXY 2: OXY 2: PPX 2: PPX 2: Therefore, it is Negative for Therefore, it is Preliminary all tests. for THC test. All Step 1: Prepare the Test Step 3: Activate the Test Ctrl CtrlCtrl Positive D1 D1D1 other tests are Negative. • Collect fresh urine in the Collection Cup. Tilt the cup on its legs to activate the test. D2 D2D2 Make sure the urine is above the minimum You can read your test results at 5 minutes, urine level line. but do not read them after 8 minutes. • Open foil pouch. Remove Test Lid from Drug 1 Drug 1 Drug 1 There is no line pouch. Discard desiccant. Example #3: There is no line Example #4: appearing in the Ctrl region ® appearing in the D2 region 1: THC 1: THC 1: OPI 1: OPI 1: AMP 1: AMP 1: BAR 1: BAR 1: BUPG 1: BUPG 1: MDMA 1: MDMA 1: 1: PCP 1: PCP 1: 1: THC 1: THC 1: OPI 1: OPI 1: AMP 1: AMP 1: BAR 1: BAR 1: BUPG 1: BUPG 1: MDMA 1: MDMA 1: 1: PCP 1: PCP 1: 1: THC 1: THC 1: OPI 1: OPI 1: AMP 1: AMP 1: BAR 1: BAR 1: BUPG 1: BUPG 1: MDMA 1: MDMA 1: 1: PCP 1: PCP 1: Drug 2 Drug 2 Drug 2 on the seventh test strip. Drug1 Drug2 on the sixth test strip. 1: PCP 1: 1: PCP 1: 1: MDMA 1: 1: MDMA 1: 1: BUPG 1: 1: BUPG 1: 1: BAR 1: 1: BAR 1: 1: AMP 1: 1: AMP 1: 1: OPI 1: 1: OPI 1: 1: THC 1: 1: THC 1: 2: PPX 2: 2: PPX 2: 2: OXY 2: 2: OXY 2: 2: TCA 2: 2: TCA 2: TCA 2: TCA 2: 2: COC 2: COC 2: MET 2: MET 2: BZO 2: BZO 2: MTD 2: MTD 2: OXY 2: OXY 2: PPX 2: PPX 2: Therefore, it is for 2: TCA 2: TCA 2: 2: COC 2: COC 2: MET 2: MET 2: BZO 2: BZO 2: MTD 2: MTD 2: OXY 2: OXY 2: PPX 2: PPX 2: 2: MTD 2: 2: TCA 2: TCA 2: 2: COC 2: COC 2: MET 2: MET 2: BZO 2: BZO 2: MTD 2: MTD 2: OXY 2: OXY 2: PPX 2: PPX 2: 2: MTD 2: 2: BZO 2: 2: BZO 2: Invalid 2: MET 2: Therefore, it is 2: MET 2: 2: COC 2: 2: COC 2: Preliminary Control Ctrl Drug 1 Drug 2 both PCP and PPX tests. All D1 Positive for OXY test. All D2 CtrlCtrl Ctrl Foil Pouch RESULTS KEY Invalid other tests are . Preliminary Positive Negative D1D1 other tests are Negative. D1 Negative Control Control Control Drug1 Drug1 Drug1 Drug2 Drug2 D2D2 D2 Drug2 firstcheckfamily.com Test Legs Collection Test Lid Cup NOTE: Any urine with a preliminary positive result should be sent to our laboratory for confirmation using the included mailer box. Minimum Urine Level First Check® Lid: DETECTION LEVELS AND APPROXIMATE DETECTION TIMES ® 5 MINUTES Drug1 1 Minimum Maximum Step 2: Screw on the Lid THC 1: THC 1: OPI 1: OPI 1: AMP 1: AMP 1: BAR 1: BAR 1: BUPG 1: BUPG 1: MDMA 1: MDMA 1: PCP 1: PCP 1: Drug Test Identifier Cut-off Level 2 2 Drug Name(s) Drug2 Detection Time Detection Time 2: COC 2: COC 2: MET 2: MET 2: BZO 2: BZO 2: MTD 2: MTD 2: TCA 2: TCA 2: OXY 2: OXY 2: PPX 2: PPX 2: Twist the lid onto the cup. The cup lid must Ctrl Control Control Line Marijuana THC 50 ng/ml 1-3 hours 1-7 days Drug Line D1 Drug 1 be closed tightly. D2 Drug 2 Test Strip RESULTS KEY Cocaine COC 150 ng/ml 2-6 hours 2-3 days Negative Preliminary Positive Invalid IMPORTANT: Cup lid must be secured Results Key Control Control Control Drug1 Drug1 Drug1 Opiates OPI 300 ng/ml 2-6 hours 1-3 days tightly by twisting Drug2 Drug2 Drug2 Dru g1 firstcheckfamily.com Drug2 Methamphetamine MET 500 ng/ml 4-6 hours 2-3 days Ctrl HC 1: T D1 I OC 1: THC D 2 2: C 1: OP 2: COC 1: OPI P it a quarter turn P 2: METET 1: AMM 2: M O 1: A Neg AR ® Con : BZ 2 ZO 1: B ative : BAR Drug1 trol 2: B 1 UPG Test Legs Drug B G 2: MTDTD 1: : M BUP 2 2 1: Preliminary Positive A RESULTS KEY 2: TCAC 1: MDMADMA Control M 2: T Y 1: P D PC P Dr ru : C g1 2: OX 1 Amphetamine AMP 500 ng/ml 4-6 hours 2-3 days : OXY ug2 2 1: P X AFTER lid is snug.
Load more

Recommended publications
  • 510(K) SUBSTANTIAL EQUIVALENCE DETERMINATION CHECKLIST
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k122633 B. Purpose for Submission: New device C. Measurand: d-Amphetamine, Secobarbital, Buprenorphine Glucuroide, Oxazepam, Benzoylecgonine, 3,4-methylenedioxymethamphetamine, Methamphetamine, Methadone, Moprhine, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline, 11-nor-∆9-Tetrahydrocannabinol- 9-carboxylic acid D. Type of Test: Qualitative lateral flow immunoassay E. Applicant: Branan Medical Corporation F. Proprietary and Established Names: ToxCup® Drug Screen Cup G. Regulatory Information: Product Classification Regulation Section Panel Code LDJ II 862.3870 Cannabinoid test system Toxicology (91) DIO II 862.3250 Cocaine and cocaine metabolite Toxicology (91) test system DJG II 862.3650 Opiate test system Toxicology (91) DJC II 862.3610 Methamphetamine test system Toxicology (91) DKZ II 862.3100 Amphetamine test system Toxicology (91) LCM unclassifed Enzyme immunoassay Phencyclidine Toxicology (91) JXM II 862.3170 Benzodiazepine test system Toxicology (91) DIS II 862.3150 Barbiturate test system Toxicology (91) DJR II 862.3620 Methadone test system Toxicology (91) LFG II 862.3910 Tricyclic antidepressant drugs Toxicology (91) test system JXN II 862.3700 Propoxyphene test system Toxicology (91) H. Intended Use: 1. Intended use(s): See indications for use below. 2. Indications(s) for use: The ToxCup Drug Screen Cup is an in vitro screening test for the rapid detection of multiple drugs and drug metabolites in human urine at or above
    [Show full text]
  • The Alkaloids: Chemistry and Biology
    CONTRIBUTORS Numbers in parentheses indicate the pages on which the authors’ contributions begin. B. EMMANUEL AKINSHOLA (135), Department of Pharmacology, College of Medicine, Howard University, Washington, DC 20059, eakinshola@ howard.edu NORMA E. ALEXANDER (293), NDA International, 46 Oxford Place, Staten Island, NY 10301, [email protected] SYED F. ALI (79, 135), Division of Neurotoxicology, National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, [email protected] KENNETH R. ALPER (1, 249), Departments of Psychiatry and Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, [email protected] MICHAEL H. BAUMANN (79), Clinical Psychopharmacology Section, Intra- mural Research Program, NIDA, National Institutes of Health, Baltimore, MD 21224, [email protected] DANA BEAL (249), Cures-not-Wars, 9 Bleecker Street, New York, NY 10012, [email protected] ZBIGNIEW K. BINIENDA (193), Division of Neurotoxicology, National Cen- ter for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, [email protected] WAYNE D. BOWEN (173), Laboratory of Medicinal Chemistry, NIDDK, NIH, Building 8 B1-23, 8 Center Drive, MSC 0820, Bethesda, MD 20892, [email protected] FRANK R. ERVIN (155), Department of Psychiatry and Human Genetics, McGill University, Montreal, Quebec H3A 2T5, Canada, md18@musica. mcgill.ca JAMES W. FERNANDEZ (235), Department of Anthropology, University of Chicago, 1126 E. 59th Street, Chicago, IL 60637, jwfi@midway. uchicago.edu xi xii CONTRIBUTORS RENATE L. FERNANDEZ (235), Department of Anthropology, University of Chicago, 1126 E. 59th Street, Chicago, IL 60637, rlf2@midway. uchicago.edu GEERTE FRENKEN (283), INTASH, P.O.
    [Show full text]
  • Characterization of Multiple Sites of Action of Ibogaine
    ——Chapter 6—— CHARACTERIZATION OF MULTIPLE SITES OF ACTION OF IBOGAINE Henry Sershen, Audrey Hashim, And Abel Lajtha Nathan Kline Institute Orangeburg, New York 10962 I. Introduction.................................................................................................................. II. Issues Related to Ibogaine in the Treatment of Drug Dependence............................. A. Dopamine as a Primary Site of Drug-Mediated Responses .................................. B. Ibogaine or Its Metabolite and Acute versus Long-Term Effect........................... C. Single or Multiple Sites of Action of Ibogaine ..................................................... III. Effect of Ibogaine on Drug-Induced Behavior............................................................ IV. Binding Site Activity ................................................................................................... A. Relevant Site of Action.......................................................................................... V. Functional Activity ...................................................................................................... VI. Stimulant Drug Actions/Behaviors.............................................................................. VII. Current Non-Ibogaine Drug Treatment Protocols ....................................................... VIII. Conclusions.................................................................................................................. References...................................................................................................................
    [Show full text]
  • Effects of Sustained Phencyclidine Exposure on Sensorimotor Gating of Startle in Rats Zoë A
    Effects of Sustained Phencyclidine Exposure on Sensorimotor Gating of Startle in Rats Zoë A. Martinez, M.A., Gaylord D. Ellison, Ph.D, Mark A. Geyer, Ph.D, and Neal R. Swerdlow, M.D., Ph.D Phencyclidine (PCP), a non-competitive NMDA which parallels the decrease observed in schizophrenia antagonist with actions at multiple other central nervous patients. In the present study, we examined changes in PPI system receptors, can cause both acute and lasting during and after sustained PCP administration, using psychoses in humans, and has also been used in cross- 5-day PCP exposure via subcutaneous osmotic minipumps, species models of psychosis. Acute exposure to PCP in rats or 14-day PCP exposure via repeated intraperitoneal produces behavioral changes, including a loss of prepulse injections. In both forms of drug delivery, PPI was inhibition (PPI) of the startle reflex, which parallels the loss disrupted during, but not after, sustained drug exposure. of PPI observed in schizophrenia patients. Sustained PPI does not appear to be sensitive to neuropathological exposure to PCP in rats produces neuropathological effects of sustained PCP exposure. changes in several limbic regions and prolonged behavioral [Neuropsychopharmacology 21:28–39, 1999] abnormalities that may parallel neuropsychological deficits © 1999 American College of Neuropsychopharmacology. in schizophrenia. It is unclear whether sustained PCP Published by Elsevier Science Inc. exposure will also produce a loss of prepulse inhibition KEY WORDS: Apomorphine; Phencyclidine; Prepulse schizophrenia is demonstrated by the significant corre- inhibition; Schizophrenia; Sensorimotor; Startle lation between PPI and measures of thought disorder (Perry and Braff 1994) and positive and negative symp- Schizophrenia patients demonstrate abnormalities in toms (Braff et al.
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • 01-Stanojlovic.Vp:Corelventura
    Acta Veterinaria (Beograd), Vol. 58, No. 2-3, 111-120, 2008. DOI: 10.2298/AVB0803111S UDK 619:616.853 EFECTS OF ETHANOL ON ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL SIGNS OF METAPHIT-INDUCED AUDIOGENIC SEIZURE STANOJLOVI] OLIVERA*, PETROVI] BOJANA*, HRN^I] D*, MLADENOVI] D**, RA[I] ALEKSANDRA* and [U[I] VESELINKA*** *Department of Physiology, School of Medicine, University of Belgrade, Serbia **Department of Pathophysiology, School of Medicine, University of Belgrade; *** Serbian Academy of Sciences and Arts, Serbia (Received 17. November 2007) The goal of the experiment was to give an answer to the question whether the simultaneous action of metaphit and audiogenic stimulation, which together lead to generalized reflex seizure in rodents, could be modified by ethanol. The rats divided in four groups received (i.p.): saline; metaphit (10 mg/kg); metaphit (10 mg/kg) + ethanol (2 g/kg); and ethanol (2 g/kg). Ethanol was administered to the metaphit-treated animals which had displayed seizures in the first eight tests. Audiogenic stimulation was applied at hourly intervals starting from the first hour after giving the metaphit injection throughout 16 hours of the experiment. For EEG recordings, three gold-plated electrodes were implanted into the rat skull. Metaphit led to hypersynchrounus epileptiform activity which forms polyspikes and spike-wave complexes. Behavior was represented by established grades of motor seizures. It was noticed that ethanol significantly decreased EEG signs of seizure, reduced the frequency as the amplitude of the waves increased (dominant ones were d and q). Ethanol completely blocked all the manifestations of the convulsive behavior of metaphit-treated animals. The results of this experiment suggest that ethanol inhibits behavioral and modifies EEG signs of the metaphit induced audiogenic generalized epilepsy.
    [Show full text]
  • B 0621 DJS1700000009 03.Pdf
    The following documentation is an electronically‐ submitted vendor response to an advertised solicitation from the West Virginia Purchasing Bulletin within the Vendor Self‐Service portal at wvOASIS.gov. As part of the State of West Virginia’s procurement process, and to maintain the transparency of the bid‐opening process, this documentation submitted online is publicly posted by the West Virginia Purchasing Division at WVPurchasing.gov with any other vendor responses to this solicitation submitted to the Purchasing Division in hard copy format. Purchasing Division State of West Virginia 2019 Washington Street East Solicitation Response Post Office Box 50130 Charleston, WV 25305-0130 Proc Folder : 311309 Solicitation Description : ADDENDUM 3 DRUG TESTING KITS AND SUPPLIES Proc Type : Central Master Agreement Date issued Solicitation Closes Solicitation Response Version 2017-04-11 SR 0621 ESR04101700000004880 1 13:30:00 VENDOR 000000221536 REDWOOD TOXICOLOGY LABORATORY INC Solicitation Number: CRFQ 0621 DJS1700000009 Total Bid : $117,980.00 Response Date: 2017-04-11 Response Time: 00:31:03 Comments: FOR INFORMATION CONTACT THE BUYER Crystal Rink (304) 558-2402 [email protected] Signature on File FEIN # DATE All offers subject to all terms and conditions contained in this solicitation Page : 1 FORM ID : WV-PRC-SR-001 Line Comm Ln Desc Qty Unit Issue Unit Price Ln Total Or Contract Amount 1 13 Panel Urine Test Kit 8000.00000 EA $5.050000 $40,400.00 Comm Code Manufacturer Specification Model # 46151606 Extended Description : 13 Panel Urine Test Kit Comments: See Pricing Page Exhibit A for more details, including optional cup item. Five business days for RTL inventory product (i.e.
    [Show full text]
  • Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands E.J
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central 344 Current Neuropharmacology, 2008, 6, 344-366 Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands E.J. Cobos1,2, J.M. Entrena1, F.R. Nieto1, C.M. Cendán1 and E. Del Pozo1,* 1Department of Pharmacology and Institute of Neuroscience, Faculty of Medicine, and 2Biomedical Research Center, University of Granada, Granada, Spain Abstract: Sigma () receptors, initially described as a subtype of opioid receptors, are now considered unique receptors. Pharmacological studies have distinguished two types of receptors, termed 1 and 2. Of these two subtypes, the 1 re- ceptor has been cloned in humans and rodents, and its amino acid sequence shows no homology with other mammalian proteins. Several psychoactive drugs show high to moderate affinity for 1 receptors, including the antipsychotic haloperi- dol, the antidepressant drugs fluvoxamine and sertraline, and the psychostimulants cocaine and methamphetamine; in ad- dition, the anticonvulsant drug phenytoin allosterically modulates 1 receptors. Certain neurosteroids are known to interact with 1 receptors, and have been proposed to be their endogenous ligands. These receptors are located in the plasma membrane and in subcellular membranes, particularly in the endoplasmic reticulum, where they play a modulatory role in 2+ intracellular Ca signaling. Sigma1 receptors also play a modulatory role in the activity of some ion channels and in sev- eral neurotransmitter systems, mainly in glutamatergic neurotransmission. In accordance with their widespread modula- tory role, 1 receptor ligands have been proposed to be useful in several therapeutic fields such as amnesic and cognitive deficits, depression and anxiety, schizophrenia, analgesia, and against some effects of drugs of abuse (such as cocaine and methamphetamine).
    [Show full text]
  • PCP Oral Fluid
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology PHENCYCLIDINE (PCP) ORAL FLUID KIT ELISA KIT INSTRUCTIONS PRODUCT # 120419 & 120415 (RTU) FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Phenylcyclidine (PCP) in human oral fluid. This assay was designed to be compatible with the Neogen NeoSal™ Oral Fluid Collection Device. DESCRIPTION Neogen Corporation’s Phenylcyclidine (PCP) ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the drug-enzyme conjugate is added and the mixture is incubated for 45 minutes at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB).
    [Show full text]
  • Modulation of Asic1a Function by Sigma-1 Receptors: Physiological and Pathophysiological Implications
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School 2-27-2009 Modulation of ASIC1a Function by Sigma-1 Receptors: Physiological and Pathophysiological Implications Yelenis Herrera University of South Florida Follow this and additional works at: https://scholarcommons.usf.edu/etd Part of the American Studies Commons Scholar Commons Citation Herrera, Yelenis, "Modulation of ASIC1a Function by Sigma-1 Receptors: Physiological and Pathophysiological Implications" (2009). Graduate Theses and Dissertations. https://scholarcommons.usf.edu/etd/2011 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Modulation of ASIC1a Function by Sigma-1 Receptors: Physiological and Pathophysiological Implications by Yelenis Herrera A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Medical Sciences Department of Molecular Pharmacology and Physiology College of Medicine University of South Florida Major Professor: Javier Cuevas, Ph.D. Keith R. Pennypacker, Ph.D. Eric S. Bennett, Ph.D. Jay B. Dean, Ph.D. Alison Willing, Ph.D. ZhiGang Xiong, Ph.D. Date of Approval: February 27, 2009 Keywords: intracellular calcium, whole-cell currents, AKAP150, calcineurin, G protein, neurotransmission, glutamate, VGCC, NMDA receptor © Copyright 2009, Yelenis Herrera DEDICATION Those who have inspired me throughout my life and scientific career are those that I love the most. This dissertation is dedicated to them - my husband and family. I would like to thank my Mom and Dad for giving me the opportunity to be free, succeed and pursue my education.
    [Show full text]
  • Mechanisms of Cocaine Abuse and Toxicity
    Mechanisms of Cocaine Abuse and Toxicity U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration I Mechanisms of Cocaine Abuse and Toxicity Editors: Doris Clouet, Ph.D. Khursheed Asghar, Ph.D. Roger Brown, Ph.D. Division of Preclinical Research National Institute on Drug Abuse NIDA Research Monograph 88 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple University School of Medicine National Federation of Parents for Philadelphia,Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic lnstitute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE, Ph.D. San Francisco, California NB Associates, Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.C. GILBERT J.
    [Show full text]
  • Curriculum Vitae
    Professor Dragan M. Djuric, MD, PhD Department: Institute of Medical Physiology “Richard Burian”, School of Medicine, University of Belgrade Address: Višegradska 26/II, 11000 Belgrade, Serbia Phone: +381 11 36 07 074 Fax: +381 11 36 11 261 E-mail: [email protected] CURRICULUM VITAE DRAGAN M. DJURIC, MD, PhD Professor and Chair, Institute of Medical Physiology “Richard Burian”, School of Medicine, University of Belgrade, President, Serbian Physiological Society Assembly, President, Serbian Association for Arteriosclerosis, Thrombosis and Vascular Biology Research Office: Institute of Medical Physiology “Richard Burian” School of Medicine, University of Belgrade Visegradska 26/II, 11000 Belgrade Republic of Serbia Phone: +381 11 36 07 074 Fax: +381 11 36 11 261 E-mail: [email protected] Personal Data Birth date: September 13, 1961 Place of birth: Krusevac, Serbia Language: English Academic Degrees MD Title: School of Medicine, University of Belgrade Graduated: 1987 Internship: School of Medicine, University of Belgrade Residency: Training in Internal Medicine, Clinical Centre of Serbia, Belgrade Certification: Board Eligible in Internal Medicine (1996); Board Certified in Clinical Physiology (2007) PhD Title: 1993, School of Medicine, University of Belgrade Undergraduate Training 1986 Department of Surgery, Ulleval Hospital, Oslo, Norway Postgraduate Study and Education 1989-1991 Endocrinology, School of Medicine, University of Belgrade 1991-1993 Experimental Physiology, School of Medicine, University of Belgrade Postdoctoral Training 1998
    [Show full text]